Last reviewed · How we verify

NCT04401956

Bread Study: Comparison of the Tolerance of Spelt and Wheat Bread

Completed NA Last updated 27 October 2021
What this trial tests

NA trial testing bread in Non-celiac Gluten Sensitivity in 24 participants. Completed in 7 September 2021.

Timeline
15 May 2020
Primary endpoint
10 August 2021
7 September 2021

Quick facts

Lead sponsorUniversity of Hohenheim
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingsingle
Primary purposesupportive care
Enrollment24
Start date15 May 2020
Primary completion10 August 2021
Estimated completion7 September 2021
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

University of Hohenheim

Who can join

Adults 18 to 70, any sex, with Non-celiac Gluten Sensitivity or Wheat Intolerance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project aims to verify the hypothesis that spelt products are more tolerable than bread wheat products in a target group of individuals with self-diagnosed wheat sensitivity. In addition, the influence of different manufacturing processes will be considered.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. No Difference in Tolerance between Wheat and Spelt Bread in Patients with Suspected Non-Celiac Wheat Sensitivity.
    Zimmermann J, Longin FH, Schweinlin A, Basrai M, et al · · 2022 · cited 5× · PMID 35889757 · DOI 10.3390/nu14142800

Verify or expand the search:

Other recruiting trials for Non-celiac Gluten Sensitivity

Currently open trials in the same condition.

Other University of Hohenheim trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04401956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing